RESUMEN
Multiple myeloma (MM) and chronic lymphocytic leukemia (CLL) cells must attach to the bone marrow (BM) microvasculature before lodging in the BM microenvironment. Using intravital microscopy (IVM) of the BM calvariae we demonstrate that the α4ß1 integrin is required for MM and CLL cell firm arrest onto the BM microvasculature, while endothelial P-selectin and E-selectin mediate cell rolling. Talin, kindlin-3 and ICAP-1 are ß1-integrin-binding partners that regulate ß1-mediated cell adhesion. We show that talin and kindlin-3 cooperatively stimulate high affinity and strength of α4ß1-dependent MM and CLL cell attachment, whereas ICAP-1 negatively regulates this adhesion. A functional connection between talin/kindlin-3 and Rac1 was found to be required for MM cell attachment mediated by α4ß1. Importantly, IVM analyses with talin- and kindlin-3-silenced MM cells indicate that these proteins are needed for cell arrest on the BM microvasculature. Instead, MM cell arrest is repressed by ICAP-1. Moreover, MM cells silenced for talin and kindlin-3, and cultured on α4ß1 ligands showed higher susceptibility to bortezomib-mediated cell apoptosis. Our results highlight the requirement of α4ß1 and selectins for the in vivo attachment of MM and CLL cells to the BM microvasculature, and indicate that talin, kindlin-3 and ICAP-1 differentially control physiological adhesion by regulating α4ß1 activity.
Asunto(s)
Médula Ósea/patología , Adhesión Celular , Endotelio Vascular/patología , Integrina alfa4beta1/metabolismo , Leucemia Linfocítica Crónica de Células B/patología , Mieloma Múltiple/patología , Proteínas Adaptadoras Transductoras de Señales , Animales , Apoptosis , Western Blotting , Médula Ósea/metabolismo , Movimiento Celular , Proliferación Celular , Citoplasma/metabolismo , Selectina E/genética , Selectina E/metabolismo , Endotelio Vascular/metabolismo , Citometría de Flujo , Humanos , Integrina alfa4beta1/genética , Péptidos y Proteínas de Señalización Intracelular/genética , Péptidos y Proteínas de Señalización Intracelular/metabolismo , Microscopía Intravital , Leucemia Linfocítica Crónica de Células B/genética , Leucemia Linfocítica Crónica de Células B/metabolismo , Proteínas de la Membrana/genética , Proteínas de la Membrana/metabolismo , Ratones , Ratones Endogámicos NOD , Ratones SCID , Microvasos , Mieloma Múltiple/genética , Mieloma Múltiple/metabolismo , Proteínas de Neoplasias/genética , Proteínas de Neoplasias/metabolismo , Selectina-P/genética , Selectina-P/metabolismo , ARN Mensajero/genética , Reacción en Cadena en Tiempo Real de la Polimerasa , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Talina/genética , Talina/metabolismo , Células Tumorales Cultivadas , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
No disponible
Asunto(s)
Humanos , Mycobacterium ulcerans/patogenicidad , Infecciones por Mycobacterium no Tuberculosas/transmisión , Mordeduras Humanas/microbiologíaRESUMEN
No disponible
Asunto(s)
Femenino , Anciano , Anciano de 80 o más Años , Humanos , Cateterismo Venoso Central/efectos adversos , Cateterismo Venoso Central/instrumentación , Falla de EquipoRESUMEN
Antisynthetase syndrome is a rare disorder, included among the idiopathic inflammatory myopathies, characterized by the presence of antisynthetase antibodies. We present a case of a patient with a suggestive clinical stage of interstitial lung disease, skin and articular disease, but without muscle involvement, with the presence of anti Jol antibodies.
Asunto(s)
Autoanticuerpos/análisis , Dermatitis/inmunología , Artropatías/inmunología , Ligasas/inmunología , Enfermedades Pulmonares Intersticiales/inmunología , Adulto , Dermatitis/complicaciones , Humanos , Artropatías/complicaciones , Enfermedades Pulmonares Intersticiales/complicaciones , Masculino , SíndromeRESUMEN
El síndrome antisintetasa (SAS) es un trastorno infrecuente, incluido entre las miopatías inflamatorias idiopáticas, que se caracteriza por la presencia de anticuerpos antisintetasa (ACAS). Presentamos el caso de un paciente con cuadro clínico consistente en afectación intersticial pulmonar,alteraciones cutáneas y articulares, pero sin afectación muscular, junto con la presencia de anticuerpos anti-Jol
Antisynthetase syndrome is a rare disorder, included among the idiopathic inflammatory myopathies, characterized by the presence of antisynthetase antibodies. We present a case of a patient with a sugestive clinical stage of interstitial lung disease, skin and articular disease, but without muscle involvement, with the presence of anti Jol antibodies
Asunto(s)
Masculino , Adulto , Humanos , Miositis/diagnóstico , Enfermedades Pulmonares Intersticiales/diagnóstico , Formación de Anticuerpos/inmunología , Ligasas/antagonistas & inhibidores , Eccema/etiología , Metilprednisolona/uso terapéutico , Enfermedades Pulmonares Intersticiales/tratamiento farmacológicoRESUMEN
Clinical treatment of B-cell chronic lymphocytic leukemia (B-CLL) is limited by the progressive drug resistance and nonselectivity of most drugs towards malignant cells. Depsipeptides are present in certain bacteria and display potent antitumor activity. We have studied the effect of the novel cyclodepsipeptide AT514 (serratamolide) from Serratia marcescens on B-CLL cell viability. AT514 induced apoptosis of B-CLL cells from the 21 patients studied, as confirmed by Annexin-V binding and nuclei condensation, with an average IC50 of 13 microM. AT514 was effective in those B-CLL cases resistant to fludarabine, but had no effect on normal PBL. AT514 preferentially activated the intrinsic apoptotic pathway, as evidenced by loss of mitochondrial membrane potential, release of cytochrome c and activation of caspase-9 and -3, but not of caspase-8. Importantly, AT514 interfered with phosphatidylinositol-3 kinase and protein kinase C survival signals since it increased the apoptotic effect of LY294002 and Bisl inhibitors, and induced Akt dephosphorylation at Ser 473. AT514 also decreased NF-kappaB activity by dramatically reducing the levels of p65 in B-CLL. This was confirmed on functional assays using NF-kappaB-luc-transfected Raji cells and transgenic mice. Our results establish that AT514 induces apoptosis of primary B-CLL cells and could be useful for clinical treatment of this malignancy.
Asunto(s)
Apoptosis/efectos de los fármacos , Leucemia Linfocítica Crónica de Células B/tratamiento farmacológico , FN-kappa B/metabolismo , Péptidos Cíclicos/farmacología , Proteínas Serina-Treonina Quinasas/metabolismo , Proteínas Proto-Oncogénicas/metabolismo , Serratia marcescens/química , Animales , Caspasa 3 , Caspasa 9 , Caspasas/metabolismo , Supervivencia Celular/efectos de los fármacos , Citocromos c/metabolismo , Depsipéptidos/farmacología , Humanos , Técnicas In Vitro , Leucemia de Células B/tratamiento farmacológico , Luciferasas/genética , Potenciales de la Membrana/efectos de los fármacos , Ratones , Ratones Transgénicos , Mitocondrias/fisiología , FN-kappa B/genética , Proteínas Proto-Oncogénicas c-akt , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Transfección , Proteína X Asociada a bcl-2RESUMEN
Apoptosis is a regulated event crucial to the development and proliferation of normal and malignant B cells. We have studied the role of signals delivered via alpha4 integrin on apoptosis triggered by three different pathways on these cells. For apoptosis induced by serum deprivation, culturing B cells on the recombinant fibronectin fragment H89, a known ligand for alpha4beta1 integrin, resulted in statistically significant (P < 0.005) higher viability values (68%, 65% and 67%) for Ramos, Nalm-6 and EHEB cells, respectively, than culturing cells on poly lysine (42%, 42% and 48%). An antialpha4 MoAb reverted the protecting effect, thus confirming that it was due specifically to alpha4 engagement. Similarly, cells cultured on FN-III4-5, a recently identified fibronectin region which binds activated alpha4 integrin, also showed statistically significant higher viability than poly lysine cultures. Alpha4 engagement however, did not prevent apoptosis induced on Ramos cells via surface IgM. Adhesion of IM-9 cells, a myeloma cell line carrying functional Fas receptors, to the H89 fragment neither increased cell viability upon triggering apoptosis via Fas when compared to poly lysine. These results indicate that alpha4 signalling may overcome B cell apoptosis induced by the lack of growth factors but does not seem to affect the IgM or Fas apoptotic pathways, thus suggesting different intracellular mechanisms for these processes.
Asunto(s)
Antígenos CD/metabolismo , Apoptosis , Linfocitos B/inmunología , Adhesión Celular , Fibronectinas/metabolismo , Linfocitos B/citología , Línea Celular , Medio de Cultivo Libre de Suero , Citoprotección , Humanos , Inmunoglobulina M/inmunología , Integrina alfa4 , Integrina alfa4beta1 , Integrinas/metabolismo , Cinética , Fragmentos de Péptidos/metabolismo , Receptores de Lipoproteína/metabolismo , Receptores Mensajeros de Linfocitos/metabolismo , Receptor fas/metabolismoRESUMEN
Tenascin-C is an adhesion-modulatory extracellular matrix molecule that is highly expressed in tumors. To investigate the effect of tenascin-C on tumor cells, we analyzed its antiadhesive nature and effect on tumor cell proliferation in a fibronectin context. Glioblastoma and breast carcinoma cell adhesion was compromised by a mixed fibronectin/tenascin-C substratum, which concomitantly caused increased tumor-cell proliferation. We identified the antiadhesive mechanism as a specific interference of tenascin-C with cell binding to the HepII/syndecan-4 site in fibronectin through direct binding of tenascin-C to the 13th fibronectin type III repeat (FNIII13). Cell adhesion and proliferation levels were restored by the addition of FNIII13. Overexpression of syndecan-4, but not syndecan-1 or -2, reverted the cell adhesion defect of tenascin-C. We characterized FNIII13 as the binding site for syndecan-4. Thus we describe a novel mechanism by which tenascin-C impairs the adhesive function of fibronectin through binding to FNIII13, thereby inhibiting the coreceptor function of syndecan-4 in fibronectin-induced integrin signaling.
Asunto(s)
Fibronectinas/metabolismo , Glicoproteínas de Membrana/metabolismo , Proteoglicanos/metabolismo , Tenascina/farmacología , Animales , Sitios de Unión , Células CHO , Adhesión Celular/efectos de los fármacos , Adhesión Celular/fisiología , División Celular/efectos de los fármacos , División Celular/fisiología , Movimiento Celular/efectos de los fármacos , Movimiento Celular/fisiología , Pollos , Cricetinae , Humanos , Fragmentos de Péptidos/metabolismo , Receptores de Fibronectina/biosíntesis , Sindecano-4 , Células Tumorales CultivadasRESUMEN
The molecular pathogenesis of B cell chronic lymphocytic leukemia (B-CLL), the most common form of leukemia, remains unknown. We have used the mRNA differential display technique to analyze genes that may be involved in the development/progression of B-CLL. We have identified the tumor suppressor retinoic acid receptor responder 3 (RARRES3) as a B-CLL-related gene. RARRES3 maps to chromosome band 11q23, a region frequently deleted in lymphoproliferative disorders. To assess the potential involvement of RARRES3 in leukemogenesis, we examined 24 cases of B-CLL, 10 of acute lymphocytic leukemia (ALL) and five related cell lines by RT-PCR and sequence analyses. We report a correlation between RARRES3 down-regulation and B-CLL progression. We also found decreased RARRES3 gene levels in ALL cases and in the five cell lines studied. We did not find mutations in any of the leukemia samples assayed, including those with 11q23 deletion. These results indicate that RARRES3 may play a role in B-CLL progression.
Asunto(s)
Genes Supresores de Tumor/genética , Leucemia Linfocítica Crónica de Células B/etiología , Receptores de Ácido Retinoico/genética , Adolescente , Adulto , Anciano , Secuencia de Aminoácidos , Línea Celular Transformada , Niño , Cromosomas Humanos Par 11/genética , Regulación hacia Abajo , Femenino , Expresión Génica , Perfilación de la Expresión Génica , Humanos , Leucemia Linfocítica Crónica de Células B/sangre , Leucemia Linfocítica Crónica de Células B/genética , Masculino , Persona de Mediana Edad , Datos de Secuencia Molecular , Leucemia-Linfoma Linfoblástico de Células Precursoras/sangre , Leucemia-Linfoma Linfoblástico de Células Precursoras/etiología , Leucemia-Linfoma Linfoblástico de Células Precursoras/genética , Proteínas/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Alineación de SecuenciaRESUMEN
Liver regeneration from the facultative hepatic stem cells, the oval cells, takes place in situations in which liver regeneration from pre-existing hepatocytes is prevented. Different models have been used to stimulate oval cell response. Many of them involve the use of carcinogenic agents with or without partial hepatectomy. In this study we show that adenovirus-mediated gene transfer of the suicide gene thymidine kinase followed by ganciclovir administration caused hepatotoxicity of variable intensity. Rats with moderate elevation in serum transaminases recovered normal liver architecture few weeks after adenovirus injection. In contrast, rats with severe liver damage exhibited a marked and persisting activation of oval cells accompanied by ductular hyperplasia. In some rats, such lesion eventually evolved to cholangiofibrosis and in one rat to cholangiocarcinoma. Deposition of fibronectin and increased number of hepatic stellate cells were found in association with oval cells and cholangiofibrotic lesions. Hepatocyte growth factor was hyperexpressed in the livers with intense oval cell response or ductular proliferation, suggesting a participation of this factor in those lesions. In summary, our data demonstrate activation of oval cell response after gene transfer of thymidine kinase followed by ganciclovir administration. These findings indicate that high doses of this therapy causes liver damage together with an impairment in hepatocellular regeneration.
Asunto(s)
Hepatopatías/genética , Hígado/metabolismo , Timidina Quinasa/genética , Adenoviridae/genética , Animales , Antivirales/farmacología , División Celular , Modelos Animales de Enfermedad , Ganciclovir/farmacología , Técnicas de Transferencia de Gen/efectos adversos , Terapia Genética/efectos adversos , Terapia Genética/métodos , Vectores Genéticos/administración & dosificación , Vectores Genéticos/genética , Factor de Crecimiento de Hepatocito/genética , Factor de Crecimiento de Hepatocito/fisiología , Hibridación in Situ , Hígado/efectos de los fármacos , Hígado/patología , Hepatopatías/patología , Hepatopatías/terapia , Masculino , Ratas , Ratas WistarRESUMEN
Endoglin is the gene mutated in hereditary hemorrhagic telangiectasia type 1 (HHT1), a dominantly inherited vascular disorder. Endoglin glycoprotein is a component of the transforming growth factor type beta (TGF-beta) receptor system which is highly expressed by endothelial cells, and at lower levels on fibroblasts and smooth muscle cells, suggesting the involvement of these lineages in the HHT1 vascular dysplasia. Overexpression of endoglin in mouse NCTC929 fibroblasts led to decreased migration in chemotactic and wound healing assays, as well as changes in the cellular morphology. When plated on uncoated surfaces, endoglin transfectants formed intercellular clusters, endoglin being not specifically localized to the cell-cell junctions, but homogenously distributed on the cellular surface. Although the expression of alpha5beta1 integrin and of an activation epitope of beta1 integrin were unchanged, a polyclonal antibody to alpha5beta1 integrin was able to inhibit cluster formation, suggesting the involvement of integrin ligand/s. In fact, coating with fibronectin, laminin, or an RGD-containing 80 kDa fragment of fibronectin were able to prevent the cellular clustering. Furthermore, synthesis of plasminogen activator inhibitor 1 (PAI-1), and to a weak extent that of fibronectin, were inhibited in endoglin transfectants. Thus, the presence of endoglin in mouse NCTC929 fibroblasts is associated with reduced production of certain extracellular matrix (ECM) components, which might explain their altered morphology, migration and intercellular cluster formation.
Asunto(s)
Adhesión Celular , Movimiento Celular , Fibroblastos/metabolismo , Molécula 1 de Adhesión Celular Vascular/metabolismo , Molécula 1 de Adhesión Celular Vascular/fisiología , Animales , Antígenos CD , Colágeno/metabolismo , Endoglina , Citometría de Flujo , Humanos , Laminina/metabolismo , Ratones , Microscopía Confocal , Inhibidor 1 de Activador Plasminogénico/metabolismo , Receptores de Superficie Celular , Receptores de Fibronectina/metabolismo , Transfección , Cicatrización de HeridasRESUMEN
B cell chronic lymphocytic leukemia (B-CLL) consists of the accumulation of malignant cells that apparently escape normal apoptotic regulation. We have studied the role of alpha4beta1 integrin/fibronectin interaction in preventing apoptosis of these cells in vitro. B cells from 16 patients showed constant expression of alpha4beta1 and little or no alpha5beta1. B-CLL cells cultured on fibronectin or two previously described fibronectin recombinant fragments (H89 and H0) which contain the ligands for alpha4beta1, consistently showed higher viability than control cells cultured on poly-lysine. The H89 fragment, containing the high affinity ligand CS-1, was the most efficient substrate with mean cell viability values of 72, 60 and 35% at days 2, 5 and 8 of culture, respectively. For control cells these values were 40, 27 and 15%, respectively. Parallel cell cycle analysis confirmed these results. The anti-apoptotic effect required direct contact with immobilized substrata since it was not observed when using B-CLL conditioned media alone or when clustering alpha4beta1 with specific mAbs in suspension. Quantitation of the apoptosis regulatory proteins Bcl-2 and Bax revealed that cells cultured on the H89 fragment showed high/moderate levels of Bcl-2 (with some interpatient variation) and low levels of Bax resulting in an elevated Bcl-2/Bax ratio. These results indicate that adhesion of B-CLL cells to fibronectin upregulate the Bcl-2/Bax ratio and this may contribute to the anti-apoptotic effect induced via alpha4beta1 integrin.
Asunto(s)
Apoptosis/fisiología , Fibronectinas/metabolismo , Integrinas/metabolismo , Leucemia Linfocítica Crónica de Células B/metabolismo , Proteínas de Neoplasias/metabolismo , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Proteínas Proto-Oncogénicas/metabolismo , Receptores Mensajeros de Linfocitos/metabolismo , Adulto , Anciano , Supervivencia Celular/fisiología , Femenino , Humanos , Integrina alfa4beta1 , Masculino , Persona de Mediana Edad , Células Tumorales Cultivadas , Proteína X Asociada a bcl-2RESUMEN
We recently reported that the heparin (Hep) III domain of fibronectin contains the H2 cell adhesion site in repeat III5 which binds activated alpha4 integrins. We have now further characterized the heparin and cell binding activities of this domain. A recombinant fragment containing repeats III4-III5 (FN-III4-5) induced Jurkat cell adhesion upon integrin activation with Mn2+ or TS2/16 monoclonal antibody (anti-beta1). Adhesion of Mn2+-treated cells to FN-III4-5 or FN-III5 fragments was inhibited by chondroitinase ABC and ACII but not by the anti-alpha4 monoclonal antibody HP2/1. In contrast, HP2/1 completely blocked adhesion of TS2/16-treated cells while chondroitinase had a partial (FN-III4-5) or minor (FN-III5) effect. Thus, the role of each receptor depended on the stimulus used to activate alpha4 beta1. The combination of HP2/1 and chondroitinase at dilutions which did not inhibit when used individually abolished adhesion of Mn2+ or TS2/16-treated cells to both fragments, indicating a cooperative effect between alpha4beta1 and chondroitin sulfate proteoglycans (CSPG). Furthermore, we have identified a 20-amino acid sequence in III5 (HBP/III5) which binds heparin and induces cell adhesion via CSPG exclusively. Although soluble HBP/III5 was a poor inhibitor, when combined with H2, it abolished adhesion to FN-III4-5 and FN-III5 fragments. These results establish that adhesion to the Hep III domain involves the cooperation of activated alpha4 beta1 and CSPG and show that HBP/III5 is a novel heparin and CSPG-binding site contributing to cell adhesion to this domain.
Asunto(s)
Adhesión Celular/fisiología , Proteoglicanos Tipo Condroitín Sulfato/fisiología , Fibronectinas/metabolismo , Heparina/metabolismo , Integrinas/fisiología , Receptores Mensajeros de Linfocitos/fisiología , Secuencia de Aminoácidos , Fibronectinas/química , Humanos , Integrina alfa4beta1 , Integrinas/metabolismo , Células Jurkat , Datos de Secuencia Molecular , Unión Proteica , Receptores Mensajeros de Linfocitos/metabolismoRESUMEN
The region of fibronectin encompassing type III repeats 4-6 contains a low affinity heparin binding domain, but its physiological significance is not clear. We have studied whether this domain is able to interact with cells as already shown for other heparin binding domains of fibronectin. A computer search based on homologies with known active sites in fibronectin revealed the sequence KLDAPT located in FN-III5. A synthetic peptide containing this sequence induced lymphoid cell adhesion upon treatment with the activating anti-beta1 monoclonal antibody (mAb) TS2/16 or with Mn2+, indicating that KLDAPT was binding to an integrin. A recombinant fragment containing repeat III5 (FN-III5) also mediated adhesion of TS2/16/Mn2+-treated cells while the FN-III6 fragment did not. Soluble KLDAPT peptide inhibited cell adhesion to FN-III5 as well as to a 38-kDa fibronectin fragment and VCAM-1, two previously known ligands for alpha4beta1 integrin. KLDAPT also competed with the binding of soluble alkaline phosphatase-coupled VCAM-Ig to Mn2+-treated alpha4beta1. Furthermore, mAbs anti-alpha4 and anti-alpha4beta7, but not mAbs to other integrins, inhibited cell adhesion to FN-III5 and KLDAPT. These results therefore establish a cell adhesive function for the FN-III5 repeat and show that KLDAPT is a novel fibronectin ligand for activated alpha4 integrins.
Asunto(s)
Adhesión Celular , Fibronectinas/química , Fibronectinas/metabolismo , Integrinas/metabolismo , Receptores Mensajeros de Linfocitos/metabolismo , Secuencia de Aminoácidos , Anticuerpos Monoclonales , Linfocitos B , Sitios de Unión , Adhesión Celular/efectos de los fármacos , Línea Celular , Humanos , Integrina alfa4beta1 , Células Jurkat , Ligandos , Manganeso/farmacología , Datos de Secuencia Molecular , Fragmentos de Péptidos/química , Fragmentos de Péptidos/metabolismo , Fragmentos de Péptidos/farmacología , Péptidos/química , Péptidos/metabolismo , Proteínas Recombinantes/química , Proteínas Recombinantes/metabolismo , Alineación de Secuencia , Linfocitos T , Células Tumorales Cultivadas , Molécula 1 de Adhesión Celular Vascular/metabolismoRESUMEN
Myeloma cells specifically localize in the bone marrow and rarely circulate in blood. To study whether this immobilization could be partially explained by the presence of constitutively activated integrins, particularly alpha4beta1, we used the activation reporter HUTS-21 anti-beta1 mAb. These analyses showed that beta1 integrins on myeloma cells were moderately active and could be upregulated similarly to integrins on lymphoma or leukemia cells. Myeloma cells were also tested for their ability to attach to RGD-containing fibronectin fragments, a property of activated (but not resting) alpha4beta1. Two cell lines adhered to these fragments and this was inhibited by anti-alpha5 but not by anti-alpha4 mAbs. These results show that myeloma cells bear low/moderately active alpha4beta1 and support the notion that multiple interactions contribute to their localization in the bone marrow.
Asunto(s)
Linfocitos B/metabolismo , Integrinas/metabolismo , Leucemia de Células B/metabolismo , Linfoma de Células B/metabolismo , Mieloma Múltiple/metabolismo , Receptores Mensajeros de Linfocitos/metabolismo , Linfocitos B/patología , Humanos , Integrina alfa4beta1 , Leucemia de Células B/patología , Linfoma de Células B/patología , Mieloma Múltiple/patología , Células Tumorales CultivadasRESUMEN
The lymphocyte integrin alpha 4 beta 1 is the receptor for the Hep II domain and CS-1 site in fibronectin (Fn) as well as for VCAM-1. We recently showed that upon activation with anti-beta 1 mAb TS2/16, alpha 4 beta 1 also recognizes the RGD Fn sequence. To determine the physiological role of these multiple interactions, we have now studied some intracellular events induced by "resting" and activated alpha 4 beta 1 binding to its different ligands. Analyses of actin and tubulin reorganization upon adhesion of B lymphoid cells to Fn fragments or VCAM-1 showed that VCAM-1, a 38 kDa fragment (Hep II+CS-1), and the CS-1 synthetic peptide induced formation of transient cytoplasmic projections; however, cells attached to a 58 kDa (Hep II) or 80 kDa (RGD) fragments remained rounded. Using transfilter assays, we showed that VCAM-1, 38 kDa and CS-1 also induced dose-dependent B cell migration mediated by alpha 4 beta 1. Furthermore, these three ligands, but not the 80 kDa fragment or a synthetic peptide (H1) containing a sequence from Hep II shown to bind alpha 4 beta 1, induced tyrosine phosphorylation of a 110 kDa protein. Activation of alpha 4 beta 1 with TS2/16 inhibited the cytoplasmic protrusions and cell migration but did not affect the pattern of phosphorylation. Our results indicate that the various alpha 4 beta 1 ligands induce different cellular responses. Most importantly they show that alpha 4 beta 1 interaction with CS-1 is sufficient to trigger intracellular events in B cells. Furthermore, they suggest a regulation by the activation form of the receptor as well as by the ligand in events involving lymphocyte adhesion and migration.
Asunto(s)
Linfocitos B/metabolismo , Proteínas del Citoesqueleto/metabolismo , Fibronectinas/metabolismo , Integrinas/metabolismo , Receptores Mensajeros de Linfocitos/metabolismo , Molécula 1 de Adhesión Celular Vascular/metabolismo , Secuencia de Aminoácidos , Adhesión Celular , Línea Celular , Movimiento Celular , Tamaño de la Célula , Fibronectinas/genética , Humanos , Integrina alfa4beta1 , Ligandos , Datos de Secuencia Molecular , Fragmentos de Péptidos/genética , Fragmentos de Péptidos/metabolismo , Fosforilación , Proteínas Serina-Treonina Quinasas/metabolismo , Proteínas Recombinantes/metabolismo , Transducción de Señal , Relación Estructura-Actividad , Molécula 1 de Adhesión Celular Vascular/genéticaAsunto(s)
Clomifeno/efectos adversos , Neuritis Óptica/inducido químicamente , Adulto , Femenino , HumanosRESUMEN
Recirculation of mouse lymphocytes to the gut involves binding of the lymphocyte integrin alpha 4 beta 7 to the mucosal vascular addressin, MAdCAM-1. In humans, indirect evidence suggests that CD4+ T cells that express high levels of alpha 4 beta 7 migrate selectively to the gut. We now report that human adult blood CD8+ T cells and B cells, like CD4+ T cells, have heterogeneous expression of alpha 4 beta 7. In contrast, NK cells, eosinophils, and newborn blood T and B cells have relatively homogeneous expression of alpha 4 beta 7. CD4+ and CD8+ T cell expression of alpha 4 beta 7 was related to age, CD45RA expression, and integrin beta 1 (CD29) expression, suggesting that alpha 4 beta 7 expression changes after primary activation of CD4+ and CD8+ T cells in vivo. To directly determine whether human alpha 4 beta 7 mediates adhesion to MAdCAM-1, we performed in vitro adhesion assays with two alpha 4 beta 7+ human lymphoma cell lines. The results indicate that human alpha 4 beta 7 is a receptor for MAdCAM-1, whereas alpha 4 beta 1 is not. Adhesion of HUT 78 cells to MAdCAM-1 required Mn2+, whereas adhesion of RPMI 8866 cells did not, suggesting that alpha 4 beta 7 may have at least two distinct functional states. The ability of lymphocytes to bind to MAdCAM-1 and recirculate to mucosal organs is likely to be influenced both by the level of alpha 4 beta 7 expression and by the functional state of the alpha 4 beta 7 molecule.